Yükleniyor... / Loading...
This study examines whether KRAS, NRAS, and BRAF mutations can be detected from circulating DNA in the blood of patients with metastatic colorectal cancer. Newly diagnosed patients aged 18 and over who have not previously received anti-EGFR therapy could take part. It was carried out as a trial without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Adult subjects with newly diagnosed, anti EGFR treatment naïve metastatic colorectal cancer * Standard of Care RAS/RAF tests performed on FFPE tumor sample as part of routine * Patient information and written informed consent form signed * Patient must be affiliated to a social security system * Age : 18 years and older Exclusion Criteria: * Patient bearing non-metastatic colorectal cancer * Patient with local relapse only * Patient with exclusive nodal metastases * Patient whose health contraindicates a 30 ml blood sample * Blood transfusion within 1 week prior blood collection * Patient having received any chemotherapy or / and radiotherapy within 15 days prior to blood collection * History of another primary cancer within the last 5 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix * Persons deprived of liberty or under supervision